Read more Meet VitroScan!
1 November 2025
In this video, Willemijn Vader explains how our ChemoPredict platform supports better treatment decisions.
Read more
Read more VitroScan will be pitching at the Dutch Life Sciences Day investors forum
31 October 2025
Meet VitroScan at the Dutch Life Sciences Conference 2025 where Willemijn Vader will be pitching at the investors forum.
Read more
Read more VitroScan awarded Kansen voor West grant to advance ex vivo tumor testing for next-generation immunotherapies
29 October 2025
VitroScan awarded 'Kansen voor West'-grant to advance ex vivo tumor testing for next-generation immunotherapies
Read more
Read more VitroScan is presenting at SITC 2025
15 October 2025
VitroScan will be presenting at the 40th Anniversary Annual Meeting of the Society of Immunology of Cancer.
Read more
Read more VitroScan will be present at Bio-Europe 2025
1 October 2025
VitroScan will be present and available to discuss how our testing solutions can help you reduce risk and maximize success in your drug development process.
Read more
Read more VitroScan's micro-tumor test accurately predicts chemotherapy response for ovarian cancer patients
9 September 2025
VitroScan is proud to announce the publication of a study showing its 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.
Read more
Read more VitroScan awarded ~ 200k Leap Medical:Forge grant
22 April 2025
We are very pleased to announce that VitroScan has received a grant of approximately 200k Euros from leap:up. The grant is part of the medical:forge Leipzig accelerator program, based in Leipzig, Germany.
Read more
Read more 'Hoe maak je het?' bij VitroScan
15 January 2025
Het Leidse radiostation Sleutelstad stuurde verslaggever Gerry van Bakel van het programma ‘Kennismakers’ naar VitroScan voor de rubriek ‘Hoe maak je het?’
Read more
Read more VitroScan awarded €1.9M by Biotech Booster to deliver chemotherapy response prediction for ovarian cancer patients
25 November 2024
VitroScan has developed ChemoPredict™, a predictive tumor testing service that revolutionizes treatment options for ovarian cancer patients.
Read more